Claims for Patent: 8,415,311

Summary for Patent: 8,415,311

Title:

Topical application of ivermectin for the treatment of dermatological conditions/afflictions

Abstract:

Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

Inventor(s):

Manetta; Vincent (Bordentown, NJ), Watkins; Gary R. (Piscataway, NJ)

Assignee:

Galderma S.A. (Cham, CH)

Application Number:

13/310,633

Patent Claims:

1. A method for the treatment of rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical
composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: an oily phase comprising dimethicone, cyclomethicone, isopropyl
palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least
one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; ivermectin; a mixture of solvents and/or propenetrating agents
selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being chemically stable over a period of time of 12
weeks.

2. The method as defined by claim 1, wherein said at least one surfactant-emulsifier is present in an amount of up to 15% by weight.

3. The method as defined by claim 1, wherein said ivermectin is present in an amount of 0.1 to 5% by weight.

4. The method as defined by claim 1 wherein said mixture of solvents and/or propenetrating agents is present in an amount of 0.1 to 20% by weight.

5. The method as defined by claim 1, wherein said one or more gelling agents is/are present in an amount of 0.01 to 5% by weight.

6. A method for the treatment of rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said
topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 3 to 50% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily
phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; up to 15% by weight of at least one surfactant-emulsifier
selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 0.1 to 20% by weight of a mixture of solvents and/or
propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being
chemically stable over a period of time of 12 weeks.

7. A method for the treatment of rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said
topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 6 to 20% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily
phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; up to 15% by weight of at least one surfactant-emulsifier
selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 0.1 to 20% by weight of a mixture of solvents and/or
propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being
chemically stable over a period of time of 12 weeks.

8. The method as defined by claim 1, wherein: said oily phase comprises dimethicone and isopropyl palmitate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol and stearyl alcohol; said at
least one surfactant-emulsifier is selected from the group consisting of sorbitan monostearate and Ceteareth-20; and said mixture of solvents and/or propenetrating agents is selected from the group consisting of propylene glycol, oleyl alcohol and
phenoxyethanol.

9. The method as defined by claim 1, wherein: said oily phase comprises dimethicone, isopropyl palmitate, cetyl alcohol and stearyl alcohol; said at least one surfactant-emulsifier is sorbitan monostearate and Ceteareth-20; and said mixture
of solvents and/or propenetrating agents is a mixture of propylene glycol, oleyl alcohol and phenoxyethanol.

11. The method as defined by claim 1, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl
para-hydroxybenzoate and sodium hydroxide.

13. The topically applicable stable pharmaceutical emulsion as defined by claim 12, wherein said at least one surfactant-emulsifier is present in an amount of up to 15% by weight.

14. The topically applicable, stable pharmaceutical emulsion as defined by claim 12, wherein said ivermectin is present in an amount of 0.1 to 5% by weight.

15. The topically applicable, stable pharmaceutical emulsion as defined by claim 12, wherein said mixture of solvents and/or propenetrating agents is present in an amount of 0.1 to 20% by weight.

16. The topically applicable, stable pharmaceutical emulsion as defined by claim 12, wherein one or more gelling agents is/are present in an amount of 0.01 to 5% by weight.

17. A topically applicable stable pharmaceutical emulsion, comprising: 3 to 50% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty
substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; up to 15% by weight of at least one surfactant-emulsifier selected from the group
consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 0.1 to 20% by weight of a mixture of solvents and/or propenetrating agents
selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being chemically stable over a
period of time of 12 weeks.

18. A topically applicable stable pharmaceutical emulsion, comprising: 6 to 20% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty
substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; up to 15% by weight of at least one surfactant-emulsifier selected from the group
consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 0.1 to 20% by weight of a mixture of solvents and/or propenetrating agents
selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being chemically stable over a
period of time of 12 weeks.

19. The topically applicable stable pharmaceutical emulsion as defined by claim 12, wherein: said oily phase comprises dimethicone and isopropyl palmitate, said oily phase further comprising fatty substances selected from the group consisting
of cetyl alcohol and stearyl alcohol; said at least one surfactant-emulsifier is selected from the group consisting of sorbitan monostearate and Ceteareth-20; and said mixture of solvents and/or propenetrating agents is selected from the group
consisting of propylene glycol, oleyl alcohol and phenoxyethanol.

20. The topically applicable pharmaceutical emulsion as defined by claim 12, wherein: said oily phase comprises dimethicone, isopropyl palmitate, cetyl alcohol and stearyl alcohol; said at least one surfactant-emulsifier is sorbitan
monostearate and Ceteareth-20; and said mixture of solvents and/or propenetrating agents is propylene glycol, oleyl alcohol and phenoxyethanol.

22. The topically applicable stable pharmaceutical emulsion as defined by claim 12, further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate,
propyl para-hydroxybenzoate and sodium hydroxide.

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.